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Abstract.  [currently 298 words. word limit = 300] 56 
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) and 57 
hospitalization in infants and children globally. Observational studies have consistently found an 58 
association between RSV LRTI in early life and subsequent respiratory morbidity, including recurrent 59 
wheeze of early childhood (RWEC) and asthma. Conversely, two randomized placebo-controlled trials of 60 
efficacious anti-RSV monoclonal antibodies (mAbs) in heterogenous infant populations found no 61 
difference in physician-diagnosed RWEC or asthma by treatment group. If a causal association exists and 62 
RSV vaccines and mAbs can prevent a substantial fraction of RWEC/asthma, the full public health value 63 
of these interventions would markedly increase. The primary alternative interpretation of the 64 
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observational data is that RSV LRTI in early life is a marker of an underlying predisposition for the 65 
development of RWEC and asthma. If this is the case, RSV vaccines and mAbs would not be expected to 66 
impact these outcomes. To evaluate whether the available evidence supports a causal association 67 
between RSV LRTI and RWEC/asthma and to provide guidance for future studies, the World Health 68 
Organization convened a meeting of subject matter experts on February 12-13, 2019 in Geneva, 69 
Switzerland. After discussing relevant background information and reviewing the current epidemiologic 70 
evidence, the group determined that: (i) the evidence is inconclusive in establishing a causal association 71 
between RSV LRTI and RWEC/asthma, (ii) the evidence does not establish that RSV mAbs and vaccines 72 
will have a substantial effect on these outcomes and (iii) regardless of the association with long-term 73 
childhood respiratory morbidity, severe acute RSV disease in young children poses a substantial public 74 
health burden and should continue to be the primary consideration for policy-setting bodies 75 
deliberating on RSV vaccine and mAb recommendations. Nonetheless, the group recognized the public 76 
health importance of resolving this question and suggested good practice guidelines for future studies. 77 
[Manuscript word limit = 5,000; current word count =4,869] 78 
1. Background and meeting objectives  79 
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) and 80 
hospitalization in children globally, causing an estimated 33.1 million LRTI episodes, 3.2 million 81 
hospitalizations, and 118,000 deaths in 2015 [1]. An estimated 45% of all hospitalizations and deaths are 82 
in infants less than 6 months of age, with 99% of global RSV mortality occurring outside of North 83 
America and Europe. The only licensed monoclonal antibody (mAb) to prevent RSV LRTI (Synagis®, 84 
palivizumab) is recommended only in high-risk infants (e.g. preterm or with certain co-morbidities) and 85 
is cost prohibitive for low and middle-income countries (LMICs). There are no licensed vaccines for RSV; 86 
however, several candidate products (e.g., vaccines and mAbs) are in clinical development [2].  87 
A long-standing question is whether RSV LRTI in early life causes subsequent recurrent wheeze of early 88 
childhood (RWEC) and asthma. The current evidence supporting a causal association between RSV and 89 
RWEC/asthma is mixed.  Understanding whether prevention of RSV can lead to reductions in rates of 90 
RWEC and asthma will contribute important information to policy decisions regarding RSV vaccines and 91 
mAbs. 92 
In order to shed light on this important question, the World Health Organization (WHO) undertook three 93 
activities. The first comprised an analysis of the sample size required to estimate the potential impact of 94 
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RSV prevention by vaccines or mAbs on the subsequent development of RWEC in RCTs [3]. The second 95 
was a systematic review and meta-analysis that will be reported separately. Third was a convening of 96 
subject matter experts on February 12-13, 2019 in Geneva, Switzerland (Agenda and Participants in 97 
Appendix A). The objectives of the meeting were: (i) to evaluate the strength of the current evidence for 98 
a causal association between early life RSV LRTI and subsequent RWEC/asthma, (ii) to evaluate the 99 
evidence that future RSV vaccines/mAbs can reduce rates of RWEC/asthma, and (iii) to provide 100 
methodological guidance for future studies. This report summarizes the meeting. 101 
2. Epidemiology of RSV LRTI 102 
Epidemiological studies have shown that more than half of children experience their first RSV infection 103 
in the first 12 months of life and almost all will have had an infection by two years of age [4]. 104 
Involvement of the lower airways occurs in 15-50% of children with primary RSV infection, with most 105 
LRTI occurring in the first 6 months of life [5].  Although children born preterm, with low birth weight, 106 
chronic lung disease, congenital heart disease, or immunosuppression have increased risk of severe 107 
disease, most children with RSV LRTI are term and otherwise healthy [6, 7]. RSV LRTI usually corresponds 108 
to a clinical diagnosis of bronchiolitis or pneumonia and is differentiated from RSV upper respiratory 109 
tract infection by lower chest wall indrawing, tachypnea, diffuse rhonchi, or wheezing [8]. Wheezing 110 
associated with the acute RSV LRTI episode can persist for up to 4 weeks (median 12 days) [9]. The case-111 
fatality ratio for RSV LRTI is low (<1%) if a child receives supportive care in a timely manner, but can be 112 
as high as 9% in low-income countries [1].   113 
3. Epidemiology of RWEC and childhood asthma 114 
Asthma represents a disease spectrum with multiple phenotypes. It has been identified by WHO as one 115 
of the most significant non-communicable diseases in people of all ages and a major source of global 116 
economic burden, with the highest rates of asthma mortality occurring in LMICs [10]. While the onset of 117 
asthma usually occurs in childhood, not all childhood asthma persists into adulthood [11]. Estimates of 118 
global childhood asthma prevalence come from the International Study of Asthma and Allergies in 119 
Childhood (ISAAC), which uses a standardized questionnaire for parent-reported history of wheeze [12]. 120 
Latin America, North America and Australia/New Zealand have the highest asthma prevalence among 121 
children 6-7 years (17-22%), but it is believed that there are high rates of undiagnosed asthma globally 122 
[13].  123 
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Asthma can be challenging to diagnose in children less than six years of age because a large proportion 124 
of young children experience viral-associated recurrent wheezing, a highly heterogenous condition that 125 
is not always indicative of asthma, and because measurements of airway obstruction using spirometry 126 
are challenging to perform in this age group and can be normal between symptomatic episodes [11, 14]. 127 
Global guidelines therefore recommend that asthma diagnosis in children less than six years of age be 128 
based on the presence of risk factors (e.g., family history of asthma/atopy, allergic sensitization) in 129 
combination with respiratory symptom patterns, response to therapeutic treatment trials, and the 130 
exclusion of alternate diagnoses [11]. As an alternative to spirometry, the forced oscillation technique 131 
(FOT) to measure respiratory system resistance and compliance has recently been shown to be a 132 
promising technique for the measurement of lung function in children as young as six weeks [15]. 133 
Asthma is believed to be caused by complex interactions between genes and the environment. 134 
Heritability estimates for asthma range from 25-95% and numerous markers of asthma risk have been 135 
identified, most notably polymorphisms at the chromosome 17q21 locus [16, 17].  Variable asthma 136 
prevalence among genetically similar populations living in different settings indicates that 137 
environmental influences are key in asthma development [18, 19], and some environmental risk factors 138 
for asthma appear to have the greatest effects in individuals with specific genetic risk variants [20, 21].  139 
4. Biologic basis for an association between early life RSV LRTI and RWEC/asthma 140 
An association between infant bronchiolitis and later development of asthma was first hypothesized in 141 
the late 1950s [22]. Subsequent experimental studies have shown that mice infected with RSV have 142 
sustained airway hyperreactivity and histologic changes characteristic of human asthma that persist 143 
after clearance of the virus [23], and that early life infection impairs regulatory T-cell function and 144 
increases susceptibility to allergic airway disease [24, 25]. In humans, increased RSV viral load  [26] and 145 
disease severity [27-29] are associated with increased risk of RWEC and/or asthma in some studies but 146 
not in others [30, 31]. In one infant cohort, a distinct nasal immune response pattern to acute RSV illness 147 
was associated with increased risk of subsequent wheeze [32].  148 
 149 
It is not well understood why some otherwise healthy infants develop severe LRTI when infected with 150 
RSV. Potential explanations include infection with a more virulent RSV strain (37-39), an aberrant host 151 
immune response [33], and/or  the presence of other pre-existent determinants of vulnerability, both 152 
genetic and environmental (e.g. smoke exposure in utero and early life, crowding, and day care 153 
attendance). If pre-existent determinants of vulnerability cause severe disease with RSV infection, it is 154 
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possible that they may also be independently predictive of an increased risk of developing RWEC and 155 
asthma in childhood.  Evidence in support of this theory is provided by a prospective cohort study that 156 
assessed passive respiratory mechanics after birth, prior to any LRTI event, and found lower lung 157 
compliance and higher resistance to be associated with increased risk for both RSV hospitalization and 158 
number of days with subsequent wheeze in the first year of life [34]. Host genetic studies of RSV illness 159 
ascribe a genetic component to risk for severe infection [35] and several shared markers of risk for both 160 
RSV LRTI and asthma have been identified [16, 36, 37]. Twin studies also suggest a trend toward a 161 
shared genetic risk for both diseases [38-40].  162 
5. Evidence for an association between early life RSV LRTI and RWEC/asthma  163 
5.1 Observational studies 164 
Most of the evidence for an association between early life RSV LRTI and subsequent RWEC and asthma 165 
comes from observational studies, of which only two have been conducted in LMICs [41, 42].  These 166 
studies can be divided into two types: prospective studies that follow longitudinal cohorts of children 167 
forward in time, assessing them regularly for RSV disease and RWEC/asthma, and retrospective studies 168 
that use administrative databases to identify children who have had documented RSV LRTI and/or 169 
RWEC/asthma in the past.    170 
The first type of prospective study is referred to here as a “medical event cohort study,” which defines 171 
exposure as an RSV LRTI inpatient or outpatient medical event, usually occurring within the first 1-2 172 
years of life. When studies compare this exposed group to those without RSV LRTI medical events, or to 173 
individuals hospitalized for a non-respiratory condition, many find a positive association between RSV 174 
LRTI and subsequent RWEC with odds ratios ranging from 3 – 36 [34, 36, 42-51] and between RSV LRTI 175 
and asthma with odds ratios ranging from  3 -17 [34, 41, 52-60]. In contrast, studies that compare 176 
individuals with RSV LRTI to those with LRTI due to other respiratory pathogens (e.g. human rhinovirus 177 
and bocavirus)  usually find no difference in the risk of subsequent RWEC/asthma [28, 30, 61-73], or find 178 
RSV LRTI to be inversely associated with these outcomes compared to the non-RSV LRTI exposed [74-179 
83].  Several studies compared the same exposure group (with RSV LRTI medical events) to both types of 180 
comparison groups and found a positive association between  RSV LRTI and RWEC/asthma when 181 
comparing exposed individuals to those without LRTI, but no significant association when compared to 182 
those with a non-RSV LRTI [36, 41, 52, 53, 75, 76, 84-88]. 183 
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The second type of prospective study is a birth cohort study in which participants are enrolled in early 184 
infancy and prospectively surveilled for respiratory illnesses and RWEC/asthma outcomes. These include 185 
high-risk birth cohorts that enroll infants born preterm and/or with a family history of asthma or atopy 186 
[20, 89-91] as well as cohorts of healthy, term infants [92-95]. Most compare children with RSV LRTI to 187 
those without LRTI of any type; some report positive associations with RWEC/asthma [90-92, 94, 96] and 188 
others find no association [20, 89, 93, 97]. Those that compare risk of RWEC/asthma in children with 189 
RSV LRTI compared to those with a non-RSV LRTI have found mixed results [95] or no difference in risk 190 
between LRTI groups with respect to future RWEC/asthma [98, 99]. 191 
A third type of prospective observational study follows non-randomized infants who received RSV mAbs 192 
[100-107] or RSV immunoglobulin [102] based on clinical indications and compares RWEC and asthma 193 
outcomes in this group to children with similar clinical profiles who did not receive RSV 194 
immunoprophylaxis. Some of these studies showed a reduction in RWEC in preschool aged children but 195 
no effect on outcomes measured at older ages [100, 101, 105], one found a reduction in RWEC in 196 
nonatopic but not in atopic children [103], and others found no difference in asthma by treatment 197 
status [106, 107]. 198 
The association between RSV and RWEC/asthma can also be evaluated retrospectively, using 199 
administrative databases such as medical records. Administrative database studies have consistently 200 
shown associations between RSV LRTI hospitalization or unspecified bronchiolitis in early life and 201 
RWEC/asthma medical events in later life [31, 108-112], although only one study required laboratory 202 
confirmation of RSV [110].  A study of children with primary RSV LRTI hospitalization before 24 months 203 
of age found that rates of subsequent asthma hospitalizations were approximately 4-fold higher in 204 
children hospitalized with first RSV LRTI between 6 and 24 months of age compared to children 205 
hospitalized with first RSV LRTI between 0 and 3 months of age  [109]. A twin database in Denmark 206 
showed no difference in asthma or lung function among monozygotic twins discordant for RSV 207 
hospitalization in early life [38-40].  208 
5.2 Randomized intervention studies 209 
Two placebo-controlled randomized controlled trials (RCTs) of RSV mAbs have assessed RWEC and/or 210 
asthma outcomes.  The first trial was an RCT of palivizumab conducted in healthy preterm Dutch infants 211 
that showed a decrease in the number of days with parent-reported wheezing in the first year of life and 212 
parent-reported current asthma at six years of age in the intervention group, but no difference in 213 
physician-diagnosed asthma or lung function at six years of age [113, 114]. The second trial was an RCT 214 
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of motavizumab, an efficacious next generation mAb that ultimately was not pursued for licensure. The 215 
motavizumab trial was conducted in healthy, term Native American infants and found no difference 216 
between treatment groups in the incidence of medically attended wheezing between one and three 217 
years of age [115].  218 
5.3 Systematic reviews of the available evidence 219 
Several systematic reviews [36, 116-118] and two meta-analyses [119, 120] have assessed the evidence 220 
for an association between RSV illness and subsequent RWEC and/or asthma.  The most recent 221 
systematic review without meta-analysis was published in 2017 as a part of a series of publications from 222 
the REGAL (RSV evidence – a Geographical Archival of the Literature) study. It included 74 publications 223 
from the United States, Canada, and Europe (including Turkey and the Russian Federation) [116].  Key 224 
findings were that early life RSV LRTI is strongly associated with RWEC and asthma persisting at least 225 
through early childhood, and with reduced lung function and increased airway reactivity. Preterm birth, 226 
Down syndrome and congenital heart disease were identified as potential effect modifiers that increase 227 
the strength of the association. A meta-analysis published in 2013 included 20 publications from 15 228 
unique studies and found that children with RSV LRTI in early life had significantly higher relative odds of 229 
wheeze and asthma in later life compared to those without RSV LRTI (OR 3.84 [95%CI 3.23, 4.58]) [119]. 230 
A second meta-analysis, published in 2019, included 41 observational studies and excluded 231 
immunoprophylaxis studies [120]. It found that compared to children without respiratory symptoms in 232 
infancy, those with laboratory confirmed RSV illness in the first year of life had higher relative odds of 233 
RWEC through three years of age (OR 3.05 [95% CI 2.50.-3.71]) and between three and six years of age 234 
(OR 2.60 [95% CI 1.67-4.04]). Between six and twelve years of age, the relative odds of RWEC (OR 2.14 235 
[95% CI 1.33-3.45]) and asthma (OR 2.95 [95% CI 1.96-4.46]) were both significantly greater in the RSV-236 
exposed group. When the comparator group was infants with a non-RSV LRTI, there was no statistically 237 
significant association with subsequent RWEC or asthma for any of the age groups and when the 238 
comparator group was infants with human rhinovirus-associated LRTI, there was an inverse association 239 
with RWEC between three and six years of age (OR 0.41 [95% CI 0.20-0.83]). Finally, the WHO has 240 
commissioned a third systematic quantitative review and meta-analysis of epidemiologic and clinical 241 
trial data that will examine testable implications from both causal and non-causal models for the 242 
association between early life RSV LRTI and subsequent wheezing illness.  A limitation of all meta-243 
analyses on this topic is that it is challenging to compare results across studies given the use of different 244 
exposure and outcome definitions and underlying differences in the populations being studied. 245 
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6. Methodological considerations in defining a causal relationship between RSV LRTI and 246 
RWEC/Asthma 247 
6.1 Observational Studies 248 
Selection bias, information bias, and confounding can each affect observational studies of RSV and 249 
RWEC/asthma. Selection bias can occur if children with severe RSV disease are more likely than those 250 
with less severe RSV LRTI to be enrolled and retained in a cohort through the study period. Information 251 
bias can occur via differential misclassification if children with a history of RSV LRTI are more prone to be 252 
diagnosed clinically with RWEC/asthma and/or undergo testing for asthma, or if children in the 253 
comparator group have RSV LRTI that is not detected. Misclassification bias can also be introduced if 254 
parents of children with RSV LRTI are more likely to report or remember wheezing episodes, and 255 
likewise, if parents of children with asthma more readily recall early RSV illness. Another potential 256 
source of misclassification bias is that many studies do not define a clear ‘washout’ period after the 257 
acute RSV illness, raising the possibility that some wheezing associated with the acute primary RSV 258 
disease episodes are misclassified as respiratory sequelae. 259 
Confounding can be another source of bias in observational studies. Studies that do not adequately 260 
control for risk factors for both RSV LRTI and RWEC/asthma such as age, prematurity, access to health 261 
care, co-morbidities, exposure to indoor air pollution and secondhand smoke, and genetic susceptibility 262 
may be subject to a confounding bias that overestimates the association. Insufficient understanding of 263 
the shared genetic susceptibility for RSV LRTI, RWEC and asthma (e.g. specific immune markers or 264 
genes) limits the possibility to control for genetic confounding in observational designs. One approach to 265 
control for genetic confounding is to study twins. Although their statistical power is limited by their 266 
small size, studies of monozygotic twins discordant for RSV hospitalization in infancy have not shown 267 
evidence of differences in asthma prevalence or lung function [38-40].  Another approach is to capitalize 268 
on a quasi-random exposure variation, such as temporal variation in viral strain virulence, or periodic 269 
absences of circulating RSV.  A specific example of this occurs annually due to the seasonal peaks of RSV 270 
circulation in temperate climates whereby children born just before the RSV season are at maximal risk 271 
for severe disease during their first few months of life when RSV circulation peaks.  A study in Tennessee 272 
found birth four months before the winter virus peak to be associated with the highest risk for 273 
developing asthma [108]. Although less prone to confounding by a shared predisposition, birth timing 274 
studies can be confounded by other seasonal phenomena, such as non-RSV respiratory pathogens, 275 
allergens and other environmental exposures.  276 
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Another consideration in interpreting observational studies is the choice of comparison group. As noted 277 
earlier, a positive association between RSV LRTI and subsequent RWEC/asthma is consistently observed 278 
in studies that compare this exposure group to a comparator group without any LRTI medical event, but 279 
not when comparing to individuals with an LRTI caused by a pathogen other than RSV. This could be 280 
interpreted as meaning that multiple respiratory viruses are causal agents for RWEC/asthma, that LRTI 281 
itself is a causal agent, or that the susceptibility to develop LRTI when infected with any respiratory virus 282 
is a marker of underlying predisposition for RWEC/asthma. 283 
Finally, although some non-randomized studies of RSV immunoprophylaxis in high-risk infants found a 284 
reduction in RWEC or better lung function in treated compared to untreated infants [100-102, 104, 105], 285 
the absence of randomization makes these studies subject to biases including confounding. Moreover,  286 
the population risk profiles and the methods to evaluate the outcomes varied considerably in these 287 
studies, making it challenging to draw inferences across them [121]. Lastly, the restriction to high-risk 288 
infants with a clinical indication for immunoprophylaxis limits the ability to generalize their results to the 289 
general infant population. 290 
 291 
6.2 Randomized controlled trials of monoclonal antibodies 292 
The greatest advantage of RCTs is that confounding by a shared predisposition for both the exposure 293 
and outcome should be eliminated. However, RCTs can be subject to misclassification bias, particularly if 294 
unmasking of the treatment assignment occurs before the end of follow up. There may have been such 295 
bias in the Dutch palivizumab RCT that showed a decrease in parent-reported asthma at six years of age 296 
after unmasking had occurred, but no difference in more objective measures including physician-297 
diagnosed asthma or lung function [113].   298 
A limitation of RCTs of RSV mAbs and vaccines is that they require very large sample sizes to detect an 299 
association with most RWEC/asthma outcomes.  A recent analysis used systematic reviews and expert 300 
opinions to test 81 sample size assumption scenarios, with risk ratios between vaccination and recurrent 301 
wheezing ranging from 0.9-1.0 for 70% of the scenarios [3]. Scenarios were ranked according to 302 
plausibility, with 75% of plausible scenarios requiring a sample size greater than 30,000 and 47% 303 
requiring a sample size greater than 100,000 mother-infants per trial arm. According to this analysis, the 304 
two mAb RCTs described above, as well as a recently completed phase III maternal RSV vaccine trial 305 
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(ClinicalTrials.gov ID: NCT02624947), would have been underpowered to find a statistically significant 306 
effect on RWEC and asthma. 307 
7. Recommendations for future studies  308 
This report summarizes many of the methodologic challenges faced by studies that aim to assess (1) 309 
whether there is a causal association between early life RSV LRTI and subsequent RWEC and asthma, or 310 
(2) whether an effective RSV preventive product could be expected to reduce the risk of subsequent 311 
RWEC/asthma.  Recognizing these limitations, the participants discussed good practices for designing 312 
and analyzing future studies in order to maximize their contribution to the evidence base. This guidance 313 
is presented in Tables 1A and 1B and summarized below:  314 
Observational studies: Additional observational studies using conventional designs were considered to 315 
be of little value in further elucidating the causal link between RSV LRTI and RWEC/asthma, with the 316 
exception of those that incorporate pre-exposure lung function assessments or a quasi-random 317 
exposure for RSV LRTI.  318 
Randomized controlled trials: RCTs were considered to be the least biased study design to assess both 319 
the questions of causal association and whether RSV preventive products can reduce subsequent 320 
RWEC/asthma, but they require investment in sufficiently powered individual trials and/or the use of 321 
standardized measures of exposure and outcome to allow pooling of data for meta-analyses.   322 
Post-introduction studies: Given the large sample sizes required by RCTs, post-introduction studies 323 
conducted after RSV vaccines/mAbs are licensed and introduced into national programs were 324 
considered to be promising strategies to address these questions. Examples include pre-post ecological 325 
studies, case-control studies, and phased introduction studies. Pre-post studies, where population-level 326 
rates of RWEC/asthma before and after vaccine introduction are compared, offer a straightforward 327 
approach but are not recommended to address these questions due to important limitations. In addition 328 
to requiring high quality pre-introduction surveillance data, they are susceptible to bias due to temporal 329 
trends in disease prevalence. This is a particular risk for asthma outcomes because asthma prevalence is 330 
not constant within communities over time and secular trends in risk factors such as diet, antibiotic use, 331 
urbanization and air pollution can be difficult to control for [122].  Case-control studies that compare 332 
vaccination status in children with and without the outcome of interest are commonly used to evaluate 333 
vaccine effectiveness post-introduction. However, such case-control studies are often biased in that 334 
unvaccinated children differ from vaccinated children in ways that are related to the outcome of 335 
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interest; in this case their propensity to be diagnosed with RWEC/asthma. Therefore, case-control 336 
studies to answer this question were felt to not be appropriate.  Phased introduction, whereby a vaccine 337 
is sequentially introduced to defined geographic areas, offers the most promising design to address 338 
whether RSV preventive products can reduce the risk of subsequent RWEC/asthma. By comparing 339 
contemporaneous cohorts of RSV-vaccinated and unvaccinated children, phased introduction addresses 340 
year-to-year variability and minimizes confounding by temporal factors. Like pre-post studies, it requires 341 
a robust surveillance system to be in place prior to vaccine introduction and to be maintained 342 
throughout the follow-up period. It also requires that populations with early access to the vaccine do 343 
not differ in important ways from populations with delayed access to the vaccine (including with respect 344 
to exposure to environmental risk factors, such as air pollution), and that outcome ascertainment does 345 
not differ by introduction group. In some situations, the areas for vaccine introduction can be randomly 346 
assigned. Examples of this are WHO’s pilot programme for the RTS,S/AS01 malaria vaccine [123], a 347 
cluster-randomized phased introduction of PCV in Mongolia [124], and the introduction of hepatitis B 348 
vaccine in The Gambia [125]. 349 
Given the limitations of each approach, a combined strategy incorporating evidence from long-term 350 
follow up of randomized trials in addition to post-introduction data will likely be required to determine 351 
whether vaccines and mAbs reduce RWEC/asthma. A challenge of all prospective study designs is 352 
retaining participants throughout the 3-5 years of follow up that are required before outcomes can be 353 
assessed. Regardless of design, all studies conducting long-term follow up should assess the 354 
comparability of those who remain in the study and those who are lost to follow-up. 355 
Finally, the meeting participants identified key variables, definitions and measurements that future 356 
studies assessing these questions should consider (Table 2). The participants recommended that the 357 
primary exposure of interest should be laboratory-confirmed RSV LRTI between birth and two years. 358 
Guidance for defining the exposure was aligned with advice from a previous WHO consultation that 359 
recommended using the Integrated Management of Childhood Illness (IMCI) definitions of LRTI [126], 360 
with inclusion of objective measures of severity such as tachypnea and oxygen saturation [127].  361 
There was agreement that the primary long-term outcomes of early life RSV LRTI that are of public 362 
health interest are RWEC, measured until at least three years of age, and asthma, measured at six years 363 
of age or later, and that studies should prioritize medically attended outcomes using standard 364 
definitions. FOT is a promising tool for objective measures of lung function in infants and young children 365 
and can be considered for use in all settings, including LMICs [15]. In clinical trials, study personnel 366 
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should remain masked to treatment allocation for the entire duration of follow up to minimize bias in 367 
the follow up of long-term outcomes, particularly since infants will have passed the critical age for 368 
immunization once the trial has ended. Objective measures of outcomes with blinded analysis should be 369 
prioritized. 370 
Potential confounders are important to measure in observational studies to the extent possible but 371 
some, such as genetic susceptibility, are very difficult to control for.  Simple, standardized data collection 372 
methods for all co-variates of interest are preferred, with birth weight, preterm birth, and family history 373 
of asthma and atopy identified as the highest priority. Finally, although studies are unlikely to be 374 
powered to detect effect modification, information about preterm birth, Down syndrome, and 375 
congenital heart disease should be collected if available.  376 
8. Policy considerations 377 
The meeting participants agreed that, given the current knowledge of the potential public health 378 
benefit, RSV vaccine policy decisions should be based on the efficacy and impact against the primary 379 
endpoint of severe RSV LRTI in infants and young children. Definitive data on the impact of RSV 380 
vaccines/mAbs on subsequent RWEC and asthma are unlikely to be available at the time vaccine policy 381 
recommendations are made. If high-quality, robust evidence does eventually support a preventive role 382 
of RSV vaccines/mAbs for RWEC/asthma, it would likely be useful supplemental data to vaccine policy 383 
decision makers in some countries.    384 
9. Summary and Conclusions 385 
This WHO-sponsored meeting was convened to evaluate the current evidence for a causal association 386 
between RSV LRTI in young children and subsequent development of RWEC/asthma, to assess the 387 
potential for RSV vaccines and mAbs to reduce the risk of RWEC and asthma, and to provide guidance 388 
for future studies that are poised to address these questions. The evaluation of the evidence was 389 
focused on the body of epidemiological literature rather than the experimental data from animals and 390 
humans. Moreover, the application of causal modelling techniques to the epidemiologic data were not 391 
considered, but will be addressed in the forthcoming WHO commissioned systematic review and meta-392 
analysis [128]. The meeting participants concluded that most observational studies show an association 393 
between RSV LRTI and RWEC and asthma; however, the interpretation of these studies, as they were 394 
performed, is subject to potential measured and unmeasured biases.  The most compelling counter-395 
argument against a causal association is that there could be a shared predisposition for both severe RSV 396 
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disease and RWEC/asthma and that having severe disease with an RSV infection is a marker of this 397 
predisposition.  RCTs of RSV mAbs did not show efficacy against objective measures of RWEC/asthma, 398 
although they were not powered to do so.   399 
After reviewing the evidence, the participants resolved that: (i) the current epidemiological evidence is 400 
inconclusive in establishing a causal association between RSV LRTI and RWEC/asthma, (ii) the evidence 401 
does not establish that RSV mAbs and vaccines are likely to have a substantial effect on these outcomes 402 
and (iii) the prevention of severe, acute RSV disease in young children, a well-established, substantial 403 
public health burden, should continue to be the highest priority for policy-setting bodies deliberating on 404 
RSV vaccine and mAb recommendations, regardless of their impact on subsequent RWEC and asthma 405 
(Panel 1). RSV vaccine impact and economic models should limit prevention of RWEC/asthma to 406 
sensitivity analyses, and RSV vaccine policy decisions should not include impacts on RWEC/asthma 407 
prevention. 408 
Nonetheless, the participants considered that the high burden of RWEC and asthma justifies the 409 
continued study of the association between these two conditions, and that a better understanding of 410 
the association could contribute to establishing the public health value of RSV vaccines and mAbs. 411 
Regardless of whether a causal association exists, the burden of RWEC/asthma in LMICs needs to be 412 
elucidated and benchmarked to other public health priorities.  Future epidemiological studies that 413 
examine the association should follow good practice guidance (Table 1A/B) using standardized methods 414 
to collect and define key variables (Table 2).  RCTs of RSV vaccines and mAbs provide the best 415 
opportunity to probe whether a causal association exists in an unbiased way, and such studies may 416 
consider long-term follow-up of participants to measure RWEC, and if possible, asthma, using 417 
standardized methods to allow for pooled analysis.  Moreover, eventual large-scale introduction of RSV 418 
preventive products might create opportunities to assess the causal association between RSV and 419 
RWEC/asthma at a population level. Introduction design and baseline surveillance platforms should be 420 
considered prior to introductions, particularly in LMICs where data on the burden of RWEC/asthma are 421 
limited.    422 
Both RSV associated LRTI and RWEC/asthma confer a substantial disease burden in children globally.  To 423 
identify a single intervention, such an RSV vaccine or mAb, that lessens the burden of both diseases 424 
would be a fortuitous public health success.  Efforts should continue to better understand whether this 425 
can be achieved.  Nonetheless, lack of conclusive evidence for a dual preventive impact should not slow 426 
15 
 
the pursuit of new preventive approaches independently targeting each of these important diseases of 427 
childhood. 428 
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Table 1A. Study designs to assess a causal association between early life RSV lower respiratory tract infection and subsequent recurrent 

























Yes ▪ Can capture most 
exposure events 
▪ Can measure 
outcomes 
longitudinally 
▪ Can measure co-








cannot be ruled out 
▪ Loss to follow-up  
▪ Choice of 
comparison group 
can affect results 
(e.g., no LRTI vs. 
non-RSV LRTI) 
Additional studies using this 
design offer limited potential 
for further insight and should 
only be done (1) if improved 
measurements of shared 
predisposition can be 
measured (e.g., genetic 
markers), (2) if assess quasi-
random exposures to RSV LRTI 
(e.g., birth timing) or (3) if lung 
function is measured before 1st 






Short Low to 
medium 
Large No ▪ Large sample size 
available 
▪ Can evaluate 
subgroups of 
interest and effect 
modification 
▪ Can be done more 
quickly and with 
fewer resources 
compared to most 








▪ Subject to biases 
▪ Some co-variates of 
interest may not be 
available 
Additional studies using this 
design offer limited potential 
for further insight and should 
be limited to studies that can 
incorporate birth timing to 














▪ Very large sample 
size required  
▪ Requires several 
years of follow up 
▪ RSV LRTI protection 
period may be 
limited to a few 
This design has greater 
potential to establish causal 
association than observational 
studies. Individual studies 
should be powered to assess 
an RWEC/asthma outcome. If 
not possible, standardized 
















Strengths Limitations Guidance for future studies 
make meta 
analyses possible 
▪ Can measure co-
variates of interest 
prospectively 
months (in the case 
of maternal 
vaccines and mAbs) 





▪ Loss to follow up 
assessments should be used so 
that data from multiple RCTs 
can be pooled for analysis.  An 
absence of effect does not 
establish that there is not a 
causal relationship. Vaccination 
allocation should remain 
masked until the end of long-
term follow-up. If this is not 
possible, a priority should be 
placed on objective 
measurement of outcomes 
with blinded analysis. 
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Strengths Limitations Guidance for future studies 
Randomized 
controlled trials 
or vaccine probe 
studies 






make meta analyses 
possible 
▪ Very large sample 
size required 
▪ Requires several 
years of follow up 
▪ RSV LRTI 
protection period 
may be limited to 
a few months (in 
the case of 
maternal vaccines 
Acceptable, with requirement 
for standardized definitions to 
allow for meta-analyses, and 
with caveat that most 
individual trials will be 
underpowered to find an 
association. Vaccination 
allocation should remain 
masked until the end of long-
term follow-up 
















Strengths Limitations Guidance for future studies 
▪ Can measure co-














Short2 Medium Small- 
medium 
Yes ▪ Relatively quick to 
conduct 
▪ Smaller sample size 
needed   












to reliably obtain 
retrospectively 
▪ Attribution risk of 
RSV causing 
asthma likely small 
Not recommended in most 
settings due to high risk of 

















▪ Large sample sizes 
are potentially 
available 
▪ Selection bias is not 
a factor 






Not recommended in most 
settings due to unclear 
temporal trends in asthma 
prevalence. It is unknown 
whether recurrent wheeze of 
early childhood is also subject 


























incidence must be 
established over 
several years 




Long High Large Yes ▪ Provides for a 
contemporaneous 
comparison group 




could differ in 
terms of temporal 
trends and other 
confounding 
factors, leading to 
bias 
▪ Not feasible 
everywhere due to 
policy constraints 




Acceptable, if appropriate 
surveillance is in place and if 
potential confounders can be 
identified and adequately 
controlled for. 
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Table 2. Key variables, definitions and measurements for future studies of the association between RSV lower respiratory tract infection and 
subsequent recurrent wheeze of early childhood (RWEC) and asthma 
Defining the exposure: 
 
• Exposure period 
o Between birth and two years, may vary by study design 
• Microbiological confirmation:  
o Assays that allow for identification of RSV viral strains (A/B) are optimal 
o Multiplex PCR assays should be used to identify co-infecting respiratory pathogens, when possible  
o RSV gene sequencing and RSV serology at 12 months of age in conjunction with methods above 
are lower priority but can be considered along with the other diagnostic methods 
• Definition of lower respiratory tract infection (LRTI):  
o The LRTI clinical case definition should be based on Integrated Management of Childhood Illness 
(IMCI) criteria  
o Both LRTI inpatient and outpatient events should be included since hospitalization criteria can vary 
widely by study setting 
• Measures of severity:  
o The following should be collected: respiratory rate, oxygen saturation, temperature, auscultation, 
cough, subcostal retractions, and difficulty breast feeding/feeding 
o Quantitative measures should be recorded using a continuous scale to allow for flexibility in 
categorization that can be compared across settings 
o A combination of these variables can be used to generate severity scores that can be compared 
across settings 
Defining the outcome: • Measuring RWEC and asthma 
o Physician report should be prioritized, including medically attended outcomes and physician use 
o Parent/caregiver reports can provide useful supplemental information when standardized 
assessments are used 
o In randomized trials, caregivers and physicians should be masked to treatment group allocation 
o Continuous outcomes (e.g. number of medically attended wheezing events) should be reported 
whenever possible. In LMIC1 settings with low literacy, phone calls are recommended over diaries. 
Audio and video clips can be used to standardize reporting 
o Medical costs and burden on the health system, absences from work and school, can be useful to 
collect depending on the setting 
• Measuring lung function 
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o Forced oscillation technique (FOT) with bronchodilation is more sensitive than spirometry for the 
detection of abnormal resistance, can be used in young children, and can be done in the field in 
LMIC settings 
• Follow up period 
o RWEC outcomes should be reported annually for each year of life, with follow up until at least 
three years of age 
o Asthma outcomes should be assessed at six years of age or later  
Potential confounders 
and effect modifiers to 
measure 
• High priority co-variates of interest 
o Birth weight, which can be a proxy for compromised lung function and development at birth 
o Preterm birth, which is associated with both RSV LRTI and RWEC/asthma, but can be difficult to 
ascertain in LMICs 
o Family history of asthma/atopy  
• Additional co-variates of interest 
o Co-infections with other respiratory pathogens 
o Other medically attended LRTIs 
o Vaccination status 
o Sex 
o Ethnic group 
o Timing of birth relative to the RSV season 
o Age at the time of first RSV LTRI illness 
o Smoke exposure (including maternal smoking during pregnancy, household smoking after birth, 
and ambient air pollution) 
o Mode of delivery (vaginal vs. caesarean section)  
o Access to health care 
o Vaccination status 
o Household crowding index 
o Nutritional status 
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Panel 1. Key points on the causal association between RSV lower respiratory tract infection and subsequent RWEC and asthma 
RSV disease in young children 
▪ The burden of RSV infection in young children is high, with almost all children having been exposed by age 2 years. Severe RSV illness 
represents a sizeable minority of all RSV infections (15-50%). 
▪ The prevention of severe RSV disease in young children is the primary outcome of RSV-illness prevention from a public health 
perspective, regardless of the causal association with RWEC/Asthma.   
Recurrent wheezing of early childhood (RWEC) and asthma 
▪ RWEC is common, occurring in approximately one-fifth of children.  The mean global estimate of asthma prevalence at age 6-7 is 
approximately 11%, with wide variation by region. 
▪ RWEC/Asthma prevalence and determinants are better understood in HICs2 than LMICs.  More data are needed in LMICs to better 
understand the burden. 
Association between RSV-LRTI and RWEC/asthma 
▪ RSV-LRTI in infancy is associated with the later development of RWEC/asthma. 
▪ Severe RSV infection with lower respiratory tract involvement is more strongly associated with the development of RWEC/asthma 
than non-severe RSV infection. 
▪ RWEC and asthma are complex conditions with multiple phenotypes, and likely multiple individual and overlapping etiologies. 
Therefore, any potential preventable fraction with RSV vaccines/mAbs is likely to be modest but may vary by population. 
Causal association between RSV-LRTI and RWEC/asthma 
▪ Epidemiologic studies and clinical trials present mixed evidence for a causal association between RSV infection and RWEC/asthma, 
which might in part be due to different study designs, methodologies, and study populations. 
▪ The state of current evidence is inconclusive in establishing a causal association between RSV infection and RWEC/asthma.  
▪ RSV vaccine impact and economic models should limit prevention of RWEC/asthma to sensitivity analyses, and RSV vaccine policy 
decisions should not include impacts on RWEC/asthma prevention. 
▪ Additional high-quality evidence addressing the question of the potential for RSV vaccines/mAbs to prevent RWEC/asthma would be 
valuable. Such studies should follow good practice guidance with respect to study design and the use of standardized measurements 
and definitions across diverse settings. 
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